title: Fluvastatin inhibits hepatitis C replication in humans.
abstract: BACKGROUND Hepatitis C viral (HCV) infection is the leading cause of death due to liver disease in the United States. Currently, pegylated interferon and ribavirin produce sustained viral remission in only 50% of patients. Additional agents are needed to increase the cure rate. In vitro experiments show strong antiviral effects of fluvastatin against HCV.
  
  
  OBJECTIVE
  To assess the safety and antiviral effects of fluvastatin in chronic HCV carriers.
  
  
  METHODS
  31 veterans with chronic HCV were prospectively given oral doses of fluvastatin, 20 to 320 mg/day, for 2-12 weeks with weekly monitoring of HCV RNA and liver tests. Reductions of viral load (P < 0.01) versus a control group were considered suppressive.
  
  
  RESULTS
  With 80 mg a day or less, 11/22 (50%) patients responded by lowering HCV RNA. The first lowering occurred within 4 weeks (9/11, 82%). The greatest weekly change in HCV RNA level was a 1.75 log(10) reduction. When lowered in responders, the viral load remained relatively constant for 2-5 weeks (7/9, 78%), or on the next test rebounded immediately to a non-significant change from, baseline (n = 2). Continued lowering of virus was seen in 2/19 (22 %) patients when the study ended. We found no evidence of liver tests worsening.
  
  
  CONCLUSIONS
  FLV used as monotherapy in vivo showed suppressive effects of HCV clinically that are modest, variable, and often short-lived. These findings support "proof-of-concept" for pilot trials combining fluvastatin with standard therapy. Statins and fluvastatin, in particular, appear to be safe for use in hepatitis C.
authors.affiliation: Veteran's Administration Medical Center, Oklahoma City, OK 73104, USA.
authors.forename: Ted
authors.initials: T
authors.lastname: Bader
authors.forename: Javid
authors.initials: J
authors.lastname: Fazili
authors.forename: Mohammed
authors.initials: M
authors.lastname: Madhoun
authors.forename: Christopher
authors.initials: C
authors.lastname: Aston
authors.forename: Diane
authors.initials: D
authors.lastname: Hughes
authors.forename: Syed
authors.initials: S
authors.lastname: Rizvi
authors.forename: Ken
authors.initials: K
authors.lastname: Seres
authors.forename: Muhammad
authors.initials: M
authors.lastname: Hasan
mesh_terms: D000284:Administration, Oral; D000328:Adult; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D000077340:Fluvastatin; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D000077340:Fluvastatin